PCRX  valuation analysis

Basics
Name: Pacira BioSciences, Inc
Description: Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. (more)
Industry: Drug Manufacturers-Specialty & Generic
Last 10Qℹ10Qs are quarterly reports which contain a company's financial figures. We use these to calculate the FFER.: Oct 29, 2020
Market cap: $3.09B (814th)
Sales(TTM): $421.10M (1141st)
Earnings(TTM): $126.12M (642nd)
Value
FFER: 0.87*
Actual price: $71.36
* Earnings were reported Feb 18, 2021 but we do not have the financials for this quarter. This is likely because the company has not yet released them. However, it might also be a problem with data quality. Regardless, you should take the FFER above with a grain of salt until we get updated financials.

Prices as of EOD 2021-03-02
Price & Estimates
Sales & Earnings history (TTM)
Notable
No notables found through heuristics.
Earnings / MarketCap
● Pacira BioSciences, Inc
● "Drug Manufacturers-Specialty & Generic" industry
Sales / MarketCap
● Pacira BioSciences, Inc
● "Drug Manufacturers-Specialty & Generic" industry
Book / MarketCap
● Pacira BioSciences, Inc
● "Drug Manufacturers-Specialty & Generic" industry
Equity / Assets
● Pacira BioSciences, Inc
● "Drug Manufacturers-Specialty & Generic" industry
ⓧ
PCRX
ⓧ
Earnings were reported Feb 18, 2021 but we do not yet have the financials for this quarter. This is probably because the company has simply not yet released their full quarterly financials. However, this might also be a problem with data quality on our end. Regardless, after earnings are released, we cannot calculate the FFER without updated financials.
ⓧ
Company description

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a non-opioid medication administered at the time of surgery to control pain while reducing opioid requirements; and iovera system, a handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company has collaboration with Aetna. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.

ⓧ
FFER components

A handful of financial components go into the FFER. Below are the relative values for PCRX. You can read more here.

Red = higher FFERs. Blue = lower FFERs.
Price/Salesvery expensive
Price/Earningsaverage
Price/Operating Incomevery expensive
Price/Bookexpensive
Debt Ratiolow
Dividend Yieldvery low
Sales growth (1y)high
Sales growth (3y)very high
Earnings growth (1y)very high
Earnings growth (3y)very high
ⓧ

Free valuation analysis for Pacira BioSciences, Inc.

Just subscribe to the mailing list. Subscription is free and gets you access to the entire S&P 1500. Already subscribed? Visit the link sent in your first welcome email to login.
Not ready? There are a lot of stocks which don't require joining like Apple,  Tesla,  Amazon,  Visa,  Disney,  etc.
Your inbox will be respected. You will get no more than two emails per month - if that.
Your privacy is important to us. We'll never share your email with any third parties.
ⓧ

Get free valuation analysis.

  • Get free access to detailed valuation analysis for most of the S&P1500.
  • Hear when other services like microcap stocks, historic valuation, or an API are made available.
  • Your inbox will be respected. You will get no more than two emails per month - if that.

Your privacy is important to us. We'll never share your email with any third parties.